“Integrating China in the International Consortium for Personalized Medicine”: The Coordination and Support Action to Foster Collaboration in Personalized Medicine Development between Europe and China,Public Health Genomics

当前位置： X-MOL 学术 › Public Health Genom. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

“Integrating China in the International Consortium for Personalized Medicine”: The Coordination and Support Action to Foster Collaboration in Personalized Medicine Development between Europe and China
Public Health Genomics ( IF 1.3 ) Pub Date : 2021-08-13 , DOI: 10.1159/000516264
Alisha Morsella _{1,

2} , Chiara Cadeddu ₂ , Carolina Castagna ₂ , Ilda Hoxhaj ₂ , Michele Sassano ₂ , Chiuhui Mary Wang ₃ , Lili Wang ₄ , Svetlana Klessova _{5,

6} , Antonio Giulio de Belvis _{1,

2} , Stefania Boccia _{2,

7} , Walter Ricciardi _{2,

8}

Affiliation

“Integrating China in the International Consortium for Personalized Medicine” (IC2PerMed) is a coordination and support action funded within the Horizon 2020 work program. Following the guidance of the International Consortium for Personalized Medicine (ICPerMed), the project’s overarching aim is to align the European Union and China’s research agendas in the field of personalized medicine (PM) to enable a swift development of PM approaches in the EU with strong leverage upon EU-Chinese collaboration. Living in the COVID-19 era, we are witnessing how the challenges imposed by the pandemic all around the globe have been acting as a catalyst for collaborations and knowledge sharing among national health systems worldwide. Given the strong interest on behalf of both Europe and China in the advancement of PM approaches, now more than ever, a cross-border collaboration between the 2 powers can accelerate the effective translation of such innovation to healthcare systems, advance research, and ensure that such change follows the directions toward the path of sustainability. IC2PerMed developments will be led by European and Chinese experts equally assembled into 3 Working Groups: (1) people and organization, (2) innovation and market, and (3) research and clinical studies in PM. This complex and dynamic network of actions thrives on dialog, cooperation, and alignment of research at national and global levels; work in the direction taken by IC2PerMed shall pave the way toward the realization of PM’s full potential, prevent it from becoming a burden for healthcare systems, and, rather, prove that it provides an essential and irreplaceable contribution to their effectiveness, efficiency, and sustainability.
Public Health Genomics

更新日期：2021-08-13

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11